109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
羟考酮与舒芬太尼用于肥胖患者腹腔镜减重手术术后恢复的比较：一项随机对照试验
Authors Yao X, Wang Z, Zhang Y, Jia W, Sheng X, Zhou Y, Xu C, Jiao H
Received 19 June 2025
Accepted for publication 10 October 2025
Published 17 October 2025 Volume 2025:19 Pages 9387—9397
DOI https://doi.org/10.2147/DDDT.S548173
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tuo Deng
Xiangyu Yao,1,* Zeyang Wang,2,* Yu Zhang,1,* Wensen Jia,1 Xinfang Sheng,1 Ye Zhou,1 Chun Xu,1 Hao Jiao3
1School of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, People’s Republic of China; 2Department of Anesthesiology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, People’s Republic of China; 3Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hao Jiao, Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People’s Republic of China, Tel +86 13512560960, Email 13512560960@139.com
Purpose: Obese patients undergoing bariatric surgery face unique challenges in postoperative pain management and recovery. Due to altered opioid pharmacokinetics and heightened pain sensitivity in this population, optimizing analgesic regimens is crucial. This study compared the impact of oxycodone- vs sufentanil-based analgesic regimens on postoperative recovery quality in obese patients undergoing bariatric surgery.
Methods: Eighty-four obese patients (BMI ≥ 30 kg/m², ASA II–III) undergoing elective laparoscopic bariatric surgery were randomized into oxycodone (n=42) or sufentanil (n=42) groups. Standardized anesthesia included either oxycodone (0.3 mg/kg at induction, 0.1 mg/kg 10 min before surgery completion) or sufentanil (0.3 μg/kg at induction, 0.1 μg/kg 10 min before surgery completion). The primary outcome was the Quality of Recovery-40 (QoR-40) score at 24 h postoperatively. Secondary outcomes included NRS pain scores, rescue analgesia requirements, adverse events (PONV and hypoxemia), sedation scores, and recovery milestones.
Results: Compared to the sufentanil group, the oxycodone group had significantly higher 24-hour QoR-40 scores (median [IQR]: 187.0 [178.8– 190.3] vs 173.0 [164.8– 184.3]; estimated median difference: 11; 95% CI: 6– 17; P< 0.001), with improved physical comfort, emotional status, physical independence, and pain (all P< 0.05). Oxycodone provided superior analgesia: lower NRS pain scores at 0.5, 2, 6, and 24 h postoperatively (all P≤ 0.003), reduced rescue analgesia in PACU (16.7% vs 50%; P=0.001) and on the ward (23.8% vs 64.3%; P< 0.001), and fewer PACU adverse events—PONV (47.6% vs 69.1%; P=0.046), antiemetic use (14.3% vs 35.7%; P=0.023), and hypoxemia (19.1% vs 50%; P=0.003). Recovery milestones (extubation, first flatus, ambulation) occurred earlier in the oxycodone group (all P< 0.05).
Conclusion: Oxycodone significantly enhanced postoperative recovery quality compared with sufentanil in obese patients undergoing laparoscopic bariatric surgery, providing superior analgesia and reducing opioid-related side effects.
Keywords: oxycodone, obesity, bariatric surgery, postoperative analgesia, quality of recovery, ERAS
1School of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, People’s Republic of China; 2Department of Anesthesiology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, People’s Republic of China; 3Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hao Jiao, Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People’s Republic of China, Tel +86 13512560960, Email 13512560960@139.com
Purpose: Obese patients undergoing bariatric surgery face unique challenges in postoperative pain management and recovery. Due to altered opioid pharmacokinetics and heightened pain sensitivity in this population, optimizing analgesic regimens is crucial. This study compared the impact of oxycodone- vs sufentanil-based analgesic regimens on postoperative recovery quality in obese patients undergoing bariatric surgery.
Methods: Eighty-four obese patients (BMI ≥ 30 kg/m², ASA II–III) undergoing elective laparoscopic bariatric surgery were randomized into oxycodone (n=42) or sufentanil (n=42) groups. Standardized anesthesia included either oxycodone (0.3 mg/kg at induction, 0.1 mg/kg 10 min before surgery completion) or sufentanil (0.3 μg/kg at induction, 0.1 μg/kg 10 min before surgery completion). The primary outcome was the Quality of Recovery-40 (QoR-40) score at 24 h postoperatively. Secondary outcomes included NRS pain scores, rescue analgesia requirements, adverse events (PONV and hypoxemia), sedation scores, and recovery milestones.
Results: Compared to the sufentanil group, the oxycodone group had significantly higher 24-hour QoR-40 scores (median [IQR]: 187.0 [178.8– 190.3] vs 173.0 [164.8– 184.3]; estimated median difference: 11; 95% CI: 6– 17; P< 0.001), with improved physical comfort, emotional status, physical independence, and pain (all P< 0.05). Oxycodone provided superior analgesia: lower NRS pain scores at 0.5, 2, 6, and 24 h postoperatively (all P≤ 0.003), reduced rescue analgesia in PACU (16.7% vs 50%; P=0.001) and on the ward (23.8% vs 64.3%; P< 0.001), and fewer PACU adverse events—PONV (47.6% vs 69.1%; P=0.046), antiemetic use (14.3% vs 35.7%; P=0.023), and hypoxemia (19.1% vs 50%; P=0.003). Recovery milestones (extubation, first flatus, ambulation) occurred earlier in the oxycodone group (all P< 0.05).
Conclusion: Oxycodone significantly enhanced postoperative recovery quality compared with sufentanil in obese patients undergoing laparoscopic bariatric surgery, providing superior analgesia and reducing opioid-related side effects.
Keywords: oxycodone, obesity, bariatric surgery, postoperative analgesia, quality of recovery, ERAS